cas 503610-43-3, N-[4-(4-Fluorophenyl)-6-(1-methylethyl)-5-[(1E)-2-[(2S,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethenyl]-2-pyrimidinyl]-N-methylmethanesulfonamide

Articles about 503610-43-3Total 17 be found

Article title
Article abstract
Author
Journal number and time
Download

Preparation method of rosuvastatin calcium
The invention provides a preparation method of rosuvastatin calcium. A rosuvastatin calcium side chain is prepared by using allene as a raw material and is used to synthesize rosuvastatin calcium. According to the method, a hydrogen peroxide-heteropoly acid oxidation system is used to oxidize the side chain from olefin to aldehyde, thereby avoiding harsh conditions of low-temperature reaction in the prior art and being more beneficial to industrial production.
-
(2019/07/05)

Synthesis method of rosuvastatin calcium
The invention provides a synthesis method of rosuvastatin calcium. Allene is taken as the raw material to prepare a bi-molecular rosuvastatin calcium side-chain intermediate. Bi-molecular allene and cyclohexanedione carry out reactions to form the bi-molecular side chain intermediate. Due to steric hindrance, in Wittig reactions, the conversion of the intermediate into cis-rosuvastatin calcium isprevented, thus the optical purity of rosuvastatin calcium is increase effectively, the product barely contains cis-rosuvastatin calcium, and moreover, the synthesis method does not a severe low temperature condition and is more suitable for industrial production.
-
Paragraph 0056-0058

(2019/06/30)

Palladium-Catalyzed Stereoselective Cyclization of in Situ Formed Allenyl Hemiacetals: Synthesis of Rosuvastatin and Pitavastatin
A diastereoselective palladium-catalyzed cyclization of allenyl hemiacetals is described. It permits the selective synthesis of 1,3-dioxane derivatives, precursors for syn-configured 1,3-diols which make an appearance in all of the statin representatives. The reaction allows the total synthesis of Rosuvastatin and Pitavastatin in a straightforward fashion.
Spreider, Pierre A.,Breit, Bernhard
supporting information
p. 3286 - 3290
(2018/06/11)

NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE
The present invention relates to the field of medicine, specifically the field of treatment and prevention of cardiovascular diseases.
-
Page/Page column 41

(2017/09/05)

ROSUVASTATIN CALCIUM AND PROCESS FOR PRODUCING INTERMEDIATE THEREOF
An object of the present invention is to provide a novel method capable of producing rosuvastatin calcium and intermediates therefor efficiently, inexpensively and with high purity. The present invention provides a method of efficiently producing rosuvastatin calcium and intermediates therefor having a high purity at an industrial scale, without using an extremely low temperature reaction or a special asymmetric catalyst.
-
Paragraph 0490; 0491

(2016/12/22)

PROCESS FOR THE PREPARATION OF STATINS IN THE PRESENCE OF BASE
The present invention relates to a process for the preparation of statins by means of a Julia-Kocienski reaction between an aldehyde and a sulfone derivative in the presence of an alkaline metal alkoxy base. The resulting derivatives are suitable as building blocks for statin type compounds such as cerivastatin, fluvastatin, pitavastatin and rosuvastatin.
-
(2013/11/19)

PROCESS FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES THEREOF
The present invention provides an improved process for preparing HMG-CoA reductase inhibitors such as rosuvasatin calcium, fluvastatin sodium, and pitavastatin calcium under a mild condition, using a novel amide-bond-containing compound having R2-N-O-R1 moiety as a key intermediate. And also, the present invention provides the novel compound, an intermediate useful for the preparation thereof, and a process for the preparation thereof.
-
(2012/01/14)

PROCESS FOR THE PREPARATION OF STATINS IN THE PRESENCE OF BASE
The present invention relates to a process for the preparation of statins by means of a Julia-Kocienski reaction between an aldehyde and a sulfone derivative in the presence of an alkaline metal alkoxy base. The resulting derivatives are suitable as building blocks for statin type compounds such as cerivastatin, fluvastatin, pitavastatin and rosuvastatin.
-
(2012/08/07)

Process for the preparation of key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
The present invention relates in general to the field of organic chemistry and in particular to a process for the preparation of 5-((E)-2-((2S,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)vinyl)-4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethanesulfonylamino)pyrimidine (RSVL) as well as a process for preparing crystalline 5-((E)-2-((2S,4R)-4-(tert-butyldimethylsilyloxy)-6-oxotetrahydro-2H-pyran-2-yl)vinyl)-4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethanesulfonylamino)pyrimidine (RSVLTBS) useful as key intermediates for the preparation of rosuvastatin or pharmaceutically acceptable salts thereof.
-
Page/Page column 12

(2011/07/06)

PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
The present invention relates in general to the field of organic chemistry and in particular to a process for the preparation of 5-((E)-2-((2S,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)vinyl)-4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethanesulfonylamino)pyrimidine (RSVL) as well as a process for preparing crystalline 5-((E)-2-((2S,4R)-4-(tert-butyldimethylsilyloxy)-6-oxotetrahydro-2H-pyran-2-yl)vinyl)-4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethanesulfonylamino)pyrimidine (RSVLTBS) useful as key intermediates for the preparation of rosuvastatin or pharmaceutically acceptable salts thereof.
-
Page/Page column 19; 20

(2011/07/07)

Lactone pathway to statins utilizing the wittig reaction. the synthesis of rosuvastatin
The first entry to statins via lactonized side chain is reported, exemplified by the synthesis of rosuvastatin. The key step is Wittig coupling of (2S,4R)-4-(tert-butyldimethylsilyloxy)-6-oxotetrahydro-2H-pyran-2-carbaldehyde and phosphonium salt of an appropriately functionalized pyrimidine heterocy'le. One-pot deprotection and hydrolysis of the resulting 4-O-TBS rosuvastatin lactone provided rosuvastatin in high yield.
Casar, Zdenko,Steinbuecher, Miha,Kosmrlj, Janez
supporting information; experimental part
p. 6681 - 6684
(2010/12/19)

PREPARATION METHOD OF STATIN COMPOUND AND BENZOTHIAZOLYL SULFONE COMPOUND USED THEREIN
The inventive method comprising subjecting a novel benzothiazolyl sulfone compound to a reaction with an aldehyde to obtain a vinyl intermediate and removing the hydroxy and carboxy protective groups of the vinyl intermediate is simple and efficient in preparing a statin compound or a salt thereof which is useful for treating hyperlipemia.
-
Page/Page column 21

(2010/08/04)

Processes for the preparation of statins, particularly rosuvastatin, and intermediates for the preparation thereof
The process for synthesis of statins featuring the use of an early intermediate (4R,6S)-6-(dialkoxymethyl)tetrahydro-2H-pyran-2,4-diol which already possesses the desired stereochemistry corresponding to final statin.
-
Page/Page column 17

(2008/12/08)

A METHOD FOR THE PRODUCTION OF THE HEMI-CALCIUM SALT OF (E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]PYRIMIDIN-5-YL](3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID
A method of producing the hemi-calcium salt of rosuvastatin, i.e. of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid of formula (I), in the crystalline or amorphous solid state, wherein a) the lactone of formula (IV), or ester or amid of general formulae (V) or (XIII), wherein X is either oxygen or amino group, R1CR2 is a protecting group, wherein R1 and R2 are preferably selected from C1 to C3 alkyls, and R is an alkyl selected from C1 to C10 alkyls, preferably methyl, ethyl or tert-butyl, after removing the protecting group in the case of the compound of formula (V), ia converted, by alkaline hydrolysis with an alkali metal or Ca2+ base, into a salt of rosuvastatin, b) in the case that an alkali metal base was used in step (a), the resulting alkali salt of rosuvastatin is converted into the calcium salt of rosuvastatin by reaction with a calcium salt in aqueous environment, c) crude calcium salt of rosuvastatin of formula (I) is extracted into a solvent partially miscible with water selected from the group including R1COOR2, R1COR2, or R1OH, wherein R1 and R2 independently mean hydrogen or a residue of a C1 to C10 aliphatic hydrocarbon, C6 aromatic hydrocarbon, C5 or C6 cyclic hydrocarbon, or a combination of an aliphatic and aromatic or cyclic hydrocarbon, d) the solution of the calcium salt of rosuvastatin prepared according to step (c) is further washed with water, and e) the product of formula (I) is isolated by cooling the solution and filtration, or by adding an anti-solvent and filtration, or by spraying into the stream of an inert gas.
-
Page/Page column 11

(2008/06/13)

PROCESS FOR PREPARING AMORPHOUS ROSUVASTATIN CALCIUM FREE OF IMPURITIES
A pure amorphous form of rosuvastatin calcium having purity of more than 99.5%, preferably a purity of more than 99.8%, more preferably a purity of more than 99.9% as determined by HPLC area percentage, and free from any traces of alkali metal impurities is disclosed. A process of preparing said pure amorphous form of rosuvastatin calcium is disclosed, which comprises hydrolysis of C1-C5 alkyl esters of rosuvastatin, preferably terf-butyl ester of rosuvastatin, with an organic nitrogen base, e.g. guanidines, amidines, amines and quaternary ammonium hydroxides, in the presence of water, optionally containing aprotic solvent, following the conversion of thus obtained rosuvastain salt with a source of calcium to desired rosuvastatin calcium, which is then isolated. An alternative process is disclosed, which comprises the conversion of numerous novel ammonium salts of rosuvastatin, preferably tert-octylammonium salt of rosuvastatin, with the source of calcium to desired commercial rosuvastatin calcium.. Rosuvastatin calcium is HMG CoA reductase, useful in the treatment of hyperlipidemia, hypercholesterolemia and atherosclerosis.
-
Page/Page column 24-25

(2008/06/13)

PROCESS FOR THE PREPARATION OF AMORPHOUS ROSUVASTATIN CALCIUM
The invention relates to processes for the preparation of amorphous rosuvastatin calcium. More particularly, it relates to the preparation of pure amorphous rosuvastain calcium and pharmaceutical compositions that include the pure amorphous rosuvastatin calcium. The invention also relates to use of said compositions for treating hyperlipidemia, hypercholesterolemia, and atherosclerosis. Formula (I).
-
Page/Page column 19

(2010/02/11)

PROCESS FOR THE MANUFACTURE OF THE CALCIUM SALT OF ROSUVATATIN (E)-7-`4- (4-FLUOROPHENYL) -6-ISOPROPYL-2-`METHYL (METHYLSULFONYL) AMINO ! PYRIMIDIN -5-YL ! (3R, 5S) -3, 5-DIHYDROXYHEPT-6-ENOIC ACID AND CRYSTALLINE INTERMEDIATES THEREOF
A process for the manufacture of the calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, useful as an HMGCoA reductase inhibitor, from a compound of the formula (7) wherein A is an acetal or ketal protecting group and R is alkyl, via isolated crystalline compounds of the formula (8) or of formula (10) is described. Crystalline intermediates of formulae 7, 8 and 10 are also described.
-
Page/Page column 22

(2010/02/11)